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ABSTRACT Psoriasis is a systemic inflammatory disease accepted as an 
independent risk factor for cardiovascular diseases (CVD). elevated levels 
and correlation of red cell distribution width (RDW) with inflammatory 
markers has recently been shown in studies investigating CVD risk and 
prognosis in rheumatoid arthritis and ankylosing spondylitis. The aim of 
this study was to evaluate levels and correlation of RDW with inflammato-
ry markers in patients with plaque psoriasis. Data including demograph-
ics, disease severity indices, laboratory parameters, and bioelectrical im-
pedance analysis was collected from medical charts of patients who were 
diagnosed with plaque psoriasis at the Hacettepe University Department 
of Dermatology between March 2014 and August 2015. Patients were 
evaluated for major CVD risk factors defined by international guidelines. 
199 patients with psoriasis and 73 volunteers were included. Patients had 
statistically significant higher values of metabolic age, visceral fat rating, 
body-mass index (BMi), red blood cells (RBC), white blood cells (WBC), 
red blood cell distribution width (RDW), alanine aminotransferase (AlT), 
uric acid, low-density lipoprotein (lDl), and C-reactive protein (CRP) 
(p=0.044, p=0.047,p=0.029, p= 0.005, p=0.02, p<0,01, p=0.001, p=0,016, 
p=0,014, p<0.01). A statistically significant relationship and positive cor-
relation between RDW and CRP levels was found in the patient group 
(p=0.01, r=0.396). Patients without major CVD risk factors (n=79) had sig-
nificantly higher values of RDW, lDl, and CRP (p=0.01, p=0.031, p=0.03, 
respectively). Patients with psoriasis who had one or more CVD risk fac-
tors (n=120) had significantly higher values of BMi, RDW, thrombocytes, 
AlT, and CRP (p=0.038, p=0.01, p=0.017, p=0.02, p=0.01, respectively).   
RDW, which is elevated as well as CRP, reflects the systemic inflamma-
tory burden and can be used for prediction of CVD in psoriasis. in fact, 
patients with psoriasis who do not have any major CVD risk factors still 
have high levels of CRP and RDW, supporting the hypothesis that psoriat-
ic inflammation itself can simultaneously cause CRP and RDW elevation. 
Coexistence of CVD risk factors is associated with AlT elevation since ad-
ditional CVD risk factors may predict psoriatic comorbidities such as non-
alcoholic fatty liver disease.
KEY WORDS: red cell distribution width, C-reactive protein, psoriasis, 
cardiovascular disease 
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INTRODUCTION
Psoriasis is an immunologically mediated, chron-
ic, recurrent, systemic inflammatory skin disease (1). 
Cardiovascular diseases (CVD) are one of the most 
important comorbidities of psoriasis (1-5). Psoriatic 
inflammation leads to development of CVD (2,4-6). in 
fact, psoriasis has been shown to be an independent 
risk factor for CVD (5,6). The increased incidence of 
CVD in psoriasis is caused by underlying systemic in-
flammation together with increased incidence of tra-
ditional CVD risk factors, which are frequently found 
in patients with psoriasis (2-6).  
The red cell distribution width (RDW) is a coeffi-
cient and shows the variation between erythrocyte 
corpuscle volumes calculated as standard deviation 
(SD) of red blood cell (RBC) volume/mean corpuscu-
lar volume (MCV) ×100 (normal range: 11.5-14.5%) 
(7). increased RDW is claimed to indicate CVD risk and 
prognosis. elevated levels of RDW and the correla-
tion with inflammatory markers have recently been 
demonstrated in studies investigating CVD and other 
chronic inflammatory diseases such as rheumatoid 
arthritis and ankylosing spondylitis (7-9). The increase 
in RDW, i.e. the increase in the difference among the 
sizes of RBC, is suggested as a consequence of the in-
flammatory effects of circulating cytokines that mod-
ulate erythropoiesis (10-12). inflammation impairs 
erythroid cell maturation and reduces erythrocyte 
circulatory half-life (13,14). iron metabolism is proven 
to be influenced by inflammatory cytokines (15). Fur-
thermore, downregulation of erythropoietin receptor 
expression and altered erythropoietin secretion is 
caused by systemic inflammation (12-16). Moreover, 
interleukin 6 (il-6) and interferon alfa (iFN-α), which 
are also known to increase and play key roles in the 
etiopathogenesis of psoriasis, have also been shown 
to be associated with RDW (13,14,16)
Therefore, the aim of this study was to evaluate 
the levels and correlation of RDW with inflammatory 
markers in patients with plaque psoriasis. RDW levels 
and other markers of inflammation were also evalu-
ated according to the presence of CVD risk factors. 
We hypothesized that the burden of psoriatic inflam-
mation can be reflected in elevated RDW levels.  
PATIENTS AND METHODS
Study population 
Data was collected from medical charts of pa-
tients who were on follow-up for plaque psoriasis at 
Hacettepe University Department of Dermatology be-
tween March 2014 and August 2015. inclusion crite-
ria for the study consisted the following: 1) existence 
of moderate to severe plaque psoriasis; 2) absence 
of any topical treatment for the past month and any 
systemic treatment for 3 months prior to evaluation 
for the study; 3) hemoglobin levels higher than >13.6 
g/dl, mean corpuscular hemoglobin (MCH) levels 
higher than 29.3 pg/cell, and mean corpuscular he-
moglobin concentration (MCHC) levels higher than 
33.6 g/dl, confirming absence of anemia. 
Patients and methods
Severity of psoriasis was determined by the psori-
asis area severity index (PASi) score and body surface 
area (BSA) involvement. Patients with a PASi score of 
5-10 and a BSA between 5-10% were classified as hav-
ing moderate psoriasis, while those with a PASi score 
higher than 10 and BSA >10% were classified as se-
vere psoriasis. Patients were evaluated for major CVD 
risk factors defined by international guidelines. Hy-
percholesterolemia and dyslipidemia were defined 
as total cholesterol 240 mg/dl or greater, low-density 
lipoprotein (lDl) cholesterol 160 mg/dl or greater, or 
high-density lipoprotein (HDl) cholesterol less than 
40 mg/dl (for persons with and without diabetes) or 
receiving cholesterol-lowering medication. Hyper-
tension was defined as systolic blood pressure 140 
mmHg or greater, diastolic blood pressure 90 mmHg 
or greater, or receiving antihypertensive medication. 
Obesity was defined as a body-mass index (BMi) of 
30.0 or greater. Diabetes mellitus was defined as fast-
ing plasma glucose 126 mg/dl or greater, 2-hour-post 
load plasma glucose 200 mg/dl or greater, hemoglo-
bin A1c (HbA1c) 6.5% or greater, or use of antihyper-
glycemic medications. Smoking was defined as cur-
rently smoking cigarettes. Prevalent CVD was defined 
as a self-reported history of myocardial infarction, 
coronary bypass surgery, balloon angioplasty, or stent 
placement in coronary arteries. Prevalence of stroke 
was ascertained from self-reported history of stroke. 
Weight, height, waist circumference, BMi, and body 
composition parameters including fat %, fat mass, fat-
free mass, muscle mass, total body water (tbw), tbw 
%, bone mass, basal metabolic rate (BMR), visceral fat 
rating, ideal body weight, and degree of obesity were 
assessed by bioelectrical impedance analysis (Tanita 
body composition analyzer SC-33OST). laboratory 
examinations consisted of total blood count (RBC, 
hemoglobin, hematocrit levels, MCV, MCH, MCHC, 
RDW, white blood cell (WBC), lymphocyte, monocyte, 
neutrophil, eosinophil, basophil, thrombocyte, MPV, 
neutrophil/lymphocyte ratio (NlR)) biochemistry 
(AlT, AST, AlP, GGT, BUN, creatinine, uric acid), fasting 
glucose, serum fasting lipid profile (total cholesterol, 
lDl, VlDl, triglyceride, HDl), folic acid, vitamin B12, 
homocysteine, and C-reactive protein. An age and 
sex-matched control group was chosen from patients 
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n=24 (33%) of the controls. There was no statistically 
significant difference between the patient and con-
trol group regarding to the presence of major CVD 
risk factors and the number of CVD risk factors they 
had (P=0.952, P=0.280, respectively).  
The body composition parameters, consisting of 
weight, fat percentage, fat mass, fat-free mass, mus-
cle mass, tbw, tbw percentage, BMR, and obesity de-
gree percentage revealed no statistically significant 
difference between the patient and control groups 
respectively (p=0.470, p=0.508, p=0.502, p=0.450, 
p=0.354, p=0.364, p=0.431, p=0.502, p=0.410, respec-
tively). However, the patient group had statistically 
significant higher values of metabolic age, visceral 
fat rating, and BMi than the control group (P=0.044, 
P=0.047, P=0.029, respectively). 
Comparisons of laboratory parameters of the pa-
tient and control groups revealed that patients had 
statistically significant higher levels of RBC, WBC, 
RDW, AlT, uric acid, lDl, and CRP (p= 0.005, p=0.02, 
p<0,01, p=0.001, p=0,016, p=0,014, p<0.01). A statis-
tically significant relationship and a positive correla-
tion between RDW values and CRP levels was found 
in patients with psoriasis (p=0.010, r=0.396)
Patient and control groups were then grouped 
according to the presence of major CVD risk factors. 
Patients who did not have any major CVD risk factors 
Body composition 
parameters 
Mean ± SD P
Weight P 89.93±93.25 0.470
C 75.95±22.61
Fat % P 27.82±9.86 0.508
C 26.17±11.21
Muscle mass P 53.88±10.67 0.354
C 51.24±14.36
BMR** P 1689.88±17.76 0.502
C 1630.00±20.82
Metabolic age P 46.68±5.29 0.044
C 37.43±5.26
Visceral fat rating P 9.23±6.71 0.047
C 6.62±4.86
BMI*** P 28.65±83.56 0.029
C 25.,98±28.70
Obesity degree % P 36.1808±83.56 0.401
C 20.4952±28.70
 
without a chronic inflammatory disease who were 
admitted to dermatology outpatient clinic for diag-
noses such as contact dermatitis, superficial cutane-
ous fungal infections, and xerosis.
Statistical analysis 
The t-test was used for continuous variables with 
normal distribution, and the Mann-Whitney U test 
was used for continuous variables without normal 
distribution. The chi-square test was used for cat-
egorical variables. Pearson correlation analysis was 
used to assess the relationships. A P value <0.05 was 
accepted as statistically significant.
RESULTS
A total of 199 patients with moderate to severe 
psoriasis and 73 volunteers for the control group were 
enrolled in the study. The mean age of the patient 
group was 43.62±14.27 (mean ± SD, while the mean 
age of the control group was 44.93±14.34. There was 
no statistically significant difference among the two 
groups according to their age (P=0.502). Of the total 
patients, 82 (41%) were women and 117 (59%) were 
men, while 28 (%38) of the controls were women 
and 45 (62%) were men; there was no statistically 
significant difference between the patient and con-
trol group according to sex (p=0.671). No major CVD 
risk factors were found in n=64 (32%) of patients and 
Figure 1. Positive correlation between red 
cell distribution width (RDW) and C-reactive 
protein (CRP) levels in patients with psoriasis. 
*A statistically significant relationship and a posi-
tive correlation between RDW values and CRP lev-
els was found win patients with psoriasis (p=0.01, 
r=0.396).
Table 1. Comparison of body composition pa-
rameters in patients with psoriasis and controls
SD: Standard Deviation; P: patient; C: control
**BMR: basal metabolic rate
***BMi: body mass index
Dogan and Atakan  Acta Dermatovenerol Croat
Red blood cell distribution in patients with psoriasis 2017;25(1):26-31
29ACTA DERMATOVENEROLOGICA CROATICA
(n=79) were compared with control group cases who 
also did not have any major CVD risk factors, where-
as patients who had one or more CVD risk factors 
(n=120) were compared with controls with one or 
more CVD risk factors. Among these subgroups, pa-
tients without any major CVD risk factors had signifi-
cantly higher values of RDW, lDl, and CRP (p=0.010, 
p=0.031, p=0.030, respectively). Patients with one or 
more CVD risk factors had significantly higher values 
of BMi, RDW, thrombocytes, AlT, and CRP (p=0.038, 
p=0.010, p=0.017, p=0.020, p=0.010, respectively).   
DISCUSSION
in this study, patients with moderate to severe 
psoriasis were shown to have significantly higher lev-
els of RDW, which was positively correlated with CRP 
levels. CRP is a well-known marker of inflammation 
and a generally accepted predictor of CVD which has 
been shown be associated with BMi and other inflam-
matory markers in patients with psoriasis (1-6,17). 
RDW levels rise when there is a difference in the sizes 
of RBC, which can be due to inflammatory effects of 
circulating cytokines that modulate erythropoiesis 
(7-9). il-6 and iFN-α are cytokines associated with 
RDW elevation which cause keratinocyte prolifera-
tion and T-cell chemoattraction in the etiopathogen-
esis of psoriasis (13,14,16). elevated RDW has been 
suggested as a risk marker in CVD, chronic hepatitis, 
and metabolic syndrome (18-20). in a recent study by 
Kim et al., RDW was shown to increase in moderate to 
severe psoriasis; however in this study the associated 
Laboratory 
parameters 
Mean ± SD P






MCV (fL) P 8657±6.46 0.161
C 87.85±5.00






NLR P 2.51±2.38 0.369
C 2.18±1.16
Platelet (103/µl) P 258637.81±74311.17 0.243
C 246142.86±79890.56






HDL (mg/dL) P 47.87±12.40 0.319
C 50.10±14.26
LDL (mg/dL) P 146.18±35.99 0.014
C 132.48±35.36
TG (mg/dL) P 2969.61±33469.96 0.516
C 155.42±85.95














ALT (U/L) P 27.46±16.73 0.001
C 20.98±10.60






Table 2. Comparison of laboratory parameters in 
patients with psoriasis and controls
SD: Standard Deviation; P: patient; C: control
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Muscle mass P 51,02±14,34 0.006
C 43,93±3,98
Tbw P 50,12±9,84 0.012
C 41,71±3,78
BMR P 53,54±6,14 0.049
C 55,31±7,70
 Laboratory parameters
RBC^ (x10^6/µl) P 4,87±0,54 0.015
C 4,61±0,28
RDW^^ (%) P 14,00±1,58 0.01
C 13,24±0,67






SD: standard deviation; P:  patient;  C: control
* Tbw: total body water
**BMR: basal metabolic rate
^RBC: red blood cell count
^^RDW: red cell distribution width
+ lDl: low density lipid
Table 3. Comparison of body composition and labora-
tory parameters in patients with psoriasis and controls 
without any major CVD risk factors.
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CVD risk factors were not evaluated, and thus the 
attribution of RDW elevation solely to psoriasis re-
mained controversial (16). in the current study, even 
patients with psoriasis who did not have any major 
CVD risk factors were shown to have higher levels of 
CRP and RDW than the controls lacking any major 
CVD risk factors. This important finding indicates that 
psoriatic inflammation itself can cause CRP and RDW 
elevation simultaneously without any concomitant 
CVD risk factor presence. Additionally, patients with 
psoriasis had higher values of metabolic age, BMi, 
and visceral fat rating than the age and sex matched 
control group with a similar profile of CVD risk factors. 
Thus, evaluation of patients with psoriasis for CVD risk 
is mandatory and RDW seems to reflect the systemic 
inflammatory burden which is predictive for CVD. 
Another important result of this study was the 
finding that BMi, visceral fat rating, lDl, and AlT lev-
els were higher in patients with psoriasis. We think 
that the presence of major CVD risk factors along 
with psoriasis causes significant differences in these 
parameters. Synchronous elevation of AlT, which is a 
specific enzyme elevating for liver pathologies, and 
visceral and blood lipid parameters brings to mind a 
probable association with non-alcoholic steatohepa-
titis (NASH). NASH is a well-known comorbidity of 
psoriasis and is a part of the spectrum of non-alco-
holic fatty liver disease (NAFlD) (21). Chronic inflam-
mation has been shown to play a significant role in 
the progression of simple fatty liver disease to NASH, 
advanced fibrosis, and cirrhosis, which are the end-
points of this spectrum. A recent study showed that 
patients with biopsy-proven NASH have higher val-
ues of RDW compared with patients with simple ste-
atosis and healthy controls (22). We believe that the 
increase of RDW in psoriasis may also be associated 
with possible NAFlD, as the patients were also shown 
to have increased visceral fat rating, lDl, and AlT 
levels. 
CONCLUSION
in conclusion, RDW was elevated in patients with 
moderate to severe psoriasis even in the absence of 
major CVD risk factors; it can be accepted as a reliable 
marker of inflammation correlating with CRP levels in 
patients with plaque psoriasis. 
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